Browse
related articles
Unique medical breakthroughs in the world of cancer
- Lebanon: Monday, June 23 - 2008 at 13:12
- PRESS RELEASE
Novartis Oncology, the leader in the industry of medicine in the cancer treatment field, recently announced new data about Zometa(Zoledronic Acid) a drug used to prevent or delay skeletal-related events in patients with advanced malignancies involving bone across a broad range of tumors.
This was announced at the Annual American Society of Clinical Oncology (ASCO) meeting held in Chicago last month.
The most important conference to deliver new scientific researches in the field of cancer worldwide.
On this note, Prof. Joseph Kattan held a press conference in Beirut, Lebanon to discuss the impact of this finding on cancer patients in the Arab region.
He explained that in Lebanon, there is more than 50% increase in breast Cancer cases in young women.
"The research we are unraveling today has proven that Zometa can serve to re-shape the way we treat cancer around the world".
The independent study was led by Dr. Michael Gnant, M.D., of the Medical University of Vienna.
The research enrolled 1,803 premenopausal women taking hormone therapy for early-stage breast cancer.
It was found that Zometa when added to hormone therapy cut by one-third the chances of cancer reoccurrence or death beyond clinical benefits achieved with hormone therapy alone.
"These important findings may well change the standard of medical practice of premenopausal women with hormone-sensitive breast cancer" Said Prof. Joseph Kattan.
"Only 30-40% of cancer patients are cured, mainly when we discover the disease in a late stage, therefore the result of this research is a revolt that expectantly will change the concept of treatment in the world of cancer, and change the horizon for many many patients." said Prof. Kattan.
Also consider reading:
Browse
related articles
- » Bahrain is best for expats in Middle East and Africa
- » Emirates is to launch flights to Amsterdam from 1st May 2010
- » Fitch downgrades Dubai Holding Commercial Operations Group to 'BB'; remains on Watch Negative
- » Dreamliner test flight expected in December
- » Ratings on four Dubai-based banks lowered and maintained on CreditWatch Negative following downgrades of Dubai GREs
Notes and media contacts
For Further Information Please Contact:Katia Yasmine, TRACCS Lebanon
Mobile + 961 70 897307
Maha Rawashdeh, TRACCS Jordan
Tel. + 9626 6 5924114
Fax. +962 6 5924334
Disclaimer:
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.
For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions
Posted by Eman Hassan
